Introduction
We recently demonstrated that atypical protein kinase Ci (PKCi) is an oncogene in non-small cell lung cancer (NSCLC; Regala et al., 2005b) . PKCi promotes anchorage-independent growth and tumorigenicity of NSCLC cells through the Rho family GTPase, Rac1 (Regala et al., 2005a) . Expression of a dominantnegative, kinase-deficient PKCi (kdPKCi) in NSCLC cells inhibits Rac1 activity, and blocks anchorageindependent growth in culture and tumorigenicity in vivo (Regala et al., 2005a) . Conversely, expression of a constitutively active Rac1 allele (RacV12) can restore anchorage-independent growth and tumorigenicity of NSCLC cells expressing kdPKCi (Regala et al., 2005a) . Transgenic overexpression of the PB1 domain of PKCi (PKCi amino acids 1-113) in NSCLC cells inhibits Rac1 activity and transformation, consistent with a role for the PB1 domain of PKCi in the regulation of Rac1 (Regala et al., 2005a) . The gold salt aurothiomalate (ATM) selectively inhibits the PB1-PB1 domain interaction between PKCi and Par6 in vitro by binding to cysteine 69 within the PB1 domain of PKCi (Erdogan et al., 2006; Stallings-Mann et al., 2006) . ATM blocks Rac1 activity and inhibits anchorage-independent growth of NSCLC cells, suggesting a role for PB1-PB1 domain interactions between PKCi and Par6 in Rac1 activation and transformation (Erdogan et al., 2006; Stallings-Mann et al., 2006) .
Here, we demonstrate the critical involvement of Par6a in NSCLC transformation. We find that Par6a is a key component of a PKCi-Par6a-Rac1 signaling axis that drives anchorage-independent growth and invasion of NSCLC cells. Reconstitution studies unambiguously demonstrate that PB1-PB1 domain interaction between PKCi and Par6a is necessary for Rac1 activity, and for anchorage-independent growth and invasion of NSCLC cells. In addition, we identify the matrix metalloproteinase-10 (MMP-10) as a critical gene target of the PKCiPar6a-Rac1 signaling axis that is required for anchorage-independent growth and invasion of NSCLC cells. Finally, we show that PKCi and MMP-10 are coordinately overexpressed in primary human NSCLC tumors, and that MMP-10 expression is predictive of poor survival of NSCLC patients. These findings demonstrate a requisite role for Par6a in PKCi-dependent transformation and identify MMP-10 as a critical effector of the PKCi-Par6a complex in NSCLC cells.
Results

PB1-PB1 domain interactions between PKCi and Par6a
are required for anchorage-independent growth and invasion of NSCLC cells We first assessed whether PB1-PB1 domain interaction between PKCi and Par6 is required for NSCLC cell transformation using interfering RNA (RNAi) technology. Human H1703 NSCLC cells were chosen for analysis as they harbor PRKCI gene amplification, a commonly observed genetic alteration that drives PKCi expression in primary NSCLC tumors (Regala et al., 2005b) . The target sequences of all RNAi reagents used in this study are given in Supplementary Figure 1 . Cell populations stably expressing two independent lentiviral RNAi constructs targeting PKCi exhibited a significant reduction in PKCi mRNA abundance and protein expression (Supplementary Figure 2A) . RNAi-mediated knockdown of PKCi correlated well with inhibition of anchorage-independent growth (Supplementary Figure  2B) , consistent with our previous finding that expression of kdPKCi inhibits anchorage-independent growth of NSCLC cells (Regala et al., 2005a) .
The atypical PKC isozymes PKCi and PKCz share B72% sequence homology at the amino-acid level, raising the possibility that RNAi to PKCi could affect PKCz expression. However, quantitative real-time PCR (qPCR) demonstrated that PKCi-RNAi had no effect on PKCz mRNA or protein expression, and that PKCzRNAi also had no effect on PKCi mRNA or protein expression ( Supplementary Figures 2C and D) . Furthermore, the inhibition of anchorage-independent growth observed in PKCi-RNAi cells was not seen in PKCzRNAi cells (Supplementary Figure 2E ). These data demonstrate that the PKCi-RNAi and PKCz-RNAi constructs are specific and that PKCi, but not PKCz, plays a critical role in anchorage-independent growth of NSCLC cells.
We used a similar approach to evaluate the role of Par6 in NSCLC cell transformation. All three human Par6 isoforms, Par6a, Par6b and Par6g, are expressed in H1703 cells (Supplementary Figure 2F) . Given its abundance, we targeted Par6a for RNAi-mediated knockdown and functional analysis. Three independent lentiviral Par6a-RNAi constructs induced efficient knockdown of Par6a mRNA expression (Supplementary Figure 2G ) and reduced anchorage-independent growth consistent with the level of Par6a mRNA knockdown (Supplementary Figure 2H) . Par6a-RNAi caused specific knockdown of Par6a expression with no appreciable effect on Par6b or Par6g mRNA abundance (Supplementary Figure 2I) . Furthermore, Par6a-RNAi had no effect on PKCi mRNA; and PKCi-RNAi had no effect on Par6a mRNA demonstrating the specificity of these RNAi constructs (Supplementary Figure 2J) . Thus, both PKCi and Par6a play a critical role in NSCLC cell anchorage-independent growth.
Expression of the PB1 domain of PKCi in NSCLC cells inhibits anchorage-independent growth (Regala et al., 2005a) . Likewise ATM, which specifically binds the PB1 domain of PKCi, inhibits anchorage-independent growth of NSCLC cells (Erdogan et al., 2006; Stallings-Mann et al., 2006) . Therefore, we assessed the ability of wild-type PKCi and two PB1 domain mutants of PKCi (PKCi-K20A and PKCi-D63A) to support anchorage-independent growth in PKCi-RNAi cells (Figure 1a) . Our most efficient PKCi-RNAi construct targeted the 3 0 -UTR of the PKCi mRNA, making it possible to achieve stable PKCi transgene expression in PKCi-RNAi cells to levels similar to that of endogenous PKCi found in NT cells (Figure 1a, inset) . Expression of either wild-type PKCi or PKCi-K20A restores anchorage-independent growth to levels similar to control NT cells whereas expression of PKCi-D63A does not ( Figure 1a ). The ability of PKCi mutants to support anchorage-independent growth correlated directly with their ability to bind Par6a (Supplementary Figure 3B) . These data strongly indicate that binding of PKCi to Par6a is important for transformation.
Par6a binds PKCi through its PB1 domain and couples to Rac1 through a distinct Cdc42, Rac1 interaction binding (CRIB) domain (Joberty et al., 2000; Noda et al., 2001) . To assess the importance of the PB1 and CRIB domains of Par6a in NSCLC transformation, we generated Par6a alleles mutated in these protein interaction domains (Supplementary Figure 3A) . Wild-type Par6a binds PKCi whereas the PB1 domain mutant Par6a-K19A does not (Supplementary Figure 3C ). The Par6a CRIB domain mutant (Par6a-DCRIB) impairs binding of Par6a to Rac1 (Qiu et al., 2000) without affecting PKCi binding (Supplementary Figure 3C) . To assess the ability of these Par6a proteins to support anchorage-independent growth, we expressed FLAG-tagged Par6a mutants in Par6a-RNAi cells ( Figure 1b ). As our most efficient Par6a-RNAi construct targeted the coding region of the Par6a mRNA, we introduced two silent mutations within the target region of the human Par6a cDNA to generate RNAi-resistant mutants as described in Supplementary Materials and methods. Immunoblot analysis demonstrated similar levels of wild-type Par6a, Par6a-K19A and Par6a-DCRIB mutants in these cells (Figure 1b, inset) . Expression of wild-type Par6a significantly restored anchorage-independent growth in Par6a-RNAi cells whereas neither the PKCi-binding mutant Par6a-K19A nor the Rac1 uncoupled mutant Par6a-DCRIB did (Figure 1b ).
H1703/NT cells grown in three-dimensional Matrigel cultures exhibited elongated cell bodies and prominent cellular protrusions invading into the surrounding matrix ( Figure 1c , left panel), morphology consistent with a highly invasive phenotype (Kleinman and Martin, 2005) . In contrast, both PKCi-RNAi and Par6a-RNAi cells exhibited rounded morphology with few cellular projections, suggesting a less invasive phenotype (Figure 1c , middle panel and right panel). Invasion assays confirmed that NT cells are highly invasive whereas PKCi-RNAi and Par6-RNAi cells exhibit a significantly reduced invasive potential (Figures 1d and e) . Invasion of PKCi-RNAi cells was significantly restored by re-expression of either wild-type PKCi or PKCi-K20A but not by PKCi-D63A ( Figure 1d ). Likewise, cellular invasion was restored in Par6a-RNAi cells by re-expression of wild-type Par6a but not Par6a-K19A or Par6a-DCRIB ( Figure 1e ). Taken together, these data demonstrate that the PB1-PB1 domain interaction between PKCi and Par6a is required for both anchorage-independent growth and invasion of NSCLC cells.
Rac1 is a critical effector of PKCi and Par6a
Our published data demonstrate that Rac1 is a critical downstream effector of PKCi in NSCLC cells (Regala et al., 2005a; Stallings-Mann et al., 2006) . Figure 1 demonstrates that Par6a plays a requisite role in transformation that involves both the PB1 domain and the CRIB domain of Par6a. These data predict that Rac1 activity in NSCLC is regulated by the PKCiPar6a complex. Consistent with this hypothesis, both PKCi-RNAi and Par6a-RNAi cells exhibited decreased Rac1 activity compared to NT cells ( Figure 2a ). Furthermore, expression of a constitutively active Rac1 mutant, RacV12, restored anchorage-independent growth in both PKCi-RNAi and Par6a-RNAi cells although having no significant effect on NT cells (Figure 2b ). Expression of RacV12 in PKCi-RNAi and Par6a-RNAi cells also restored the invasive morphology in three-dimensional Matrigel culture ( Figure 2c ) and invasion through Matrigel-coated chambers ( Figure 2d ). Thus, Rac1 is a critical effector of PKCi-Par6a in NSCLC transformation. To directly assess the importance of Rac1 in NSCLC cell transformation, we generated Rac1-RNAi cells that exhibit efficient knockdown of Rac1 mRNA and protein expression (Supplementary Figure 4A) . Rac1-RNAi cells exhibited decreased anchorage-independent growth similar to that observed in PKCi-RNAi and Par6a-RNAi cells (Supplementary Figure 4B) . Furthermore, Rac1-RNAi cells exhibit rounded morphology in threedimensional Matrigel culture and significantly reduced cellular invasion (Supplementary Figures 4C and D) . Expression of constitutively active PKCi in Rac1 RNAi cells was unable to restore cellular invasion, confirming that Rac1 is required downstream of PKCi in transformation (Supplementary Figure 4E) . Thus, Rac1 activity is regulated in NSCLC cells by the PKCi-Par6a complex and Rac1 is required downstream of this complex for NSCLC cell transformation.
Identification of MMP-10 as a target of oncogenic PKCi in NSCLC
We next determined downstream targets of PKCi involved in transformation by conducting gene expression analysis of H1703 NT and PKCi-RNAi cells (see Figure 1a ). This analysis identified 10 candidate PKCi target genes based on fold-change (>twofold) and P-value (o0.05) listed in Table 1 . PKCi was among the 10 regulated genes, confirming efficient knockdown of PKCi mRNA in the cells used for the expression analysis.
To identify PKCi target genes most likely to be relevant to the human disease, we interrogated a public domain database containing gene expression data from 35 primary human NSCLC tumors (Garber et al., 2001) for correlations between the expression of each of the nine identified genes and PKCi (Table 1 ). Kendall's t rank correlation analysis revealed that only two of the nine candidate genes, Keratin associated protein 26-1 (KRTAP 26-1) and MMP-10, showed a significant correlation with PKCi expression in primary lung tumors consistent with that observed in H1703 cells. A third gene, KDEL, showed an association with PKCi in primary tumors that was opposite to that predicted from the expression analysis of H1703 cells. MMP-10, also known as stromelysin 2, was judged to be the most promising candidate as a target for PKCimediated transformation and was subjected to further analysis.
MMP-10 expression is regulated through the PKCi-Par6a-Rac1 signaling axis We next assessed whether MMP-10 expression is regulated through the PKCi-Par6a-Rac1 signaling axis. qPCR analysis revealed that MMP-10 expression is significantly inhibited in PKCi-RNAi, Par6a-RNAi and Rac-RNAi NSCLC cells when compared to NT control cells (Figure 3a) . Furthermore, expression of wild-type Par6a in Par6a-RNAi cells restored MMP-10 expression whereas neither Par6a-K19A nor Par6a-DCRIB did so (Figure 3b ). Finally, expression of RacV12 in PKCi-RNAi and Par6a-RNAi cells restored MMP-10 expression to levels comparable to NT cells while having little effect on MMP-10 expression in NT cells (Figure 3c ). Thus, MMP-10 expression is regulated through the PKCi-Par6a-Rac1 signaling axis.
MMP-10 is required for anchorage-independent growth and invasion of NSCLC cells We next assessed whether MMP-10 plays an important role in NSCLC transformation. Two independent RNAi constructs targeting MMP-10 significantly knocked down MMP-10 RNA abundance (Figure 4a ) and caused a commensurate inhibition of anchorage-independent growth (Figure 4b) . A similar inhibition of anchorageindependent growth was observed in cells treated with the general MMP inhibitor GM6001 (Figure 4b ). MMP-10-RNAi inhibited MMP-10 mRNA but had no effect on PKCi, Par6a or Rac1 mRNA abundance (Figure 4c) indicating that the cellular effects of MMP-10 knockdown are not caused by regulating expression these genes. In addition, both MMP-10-RNAi cells and cells treated with GM6001, exhibited rounded morphology in three-dimensional Matrigel cultures ( Figure 4d ) and reduced invasion through Matrigel-coated chambers (Figure 4e ). Thus, MMP-10 plays a critical role in NSCLC anchorage-independent growth and invasion of NSCLC cells.
MMP-10 is a critical effector of PKCi-mediated transformation
We next assessed whether MMP-10 is a critical effector of the oncogenic PKCi-Par6a-Rac1 signaling axis. For this purpose, we assessed the ability of catalytically active recombinant MMP-10 enzyme to reconstitute anchorage-independent growth (Figure 5a anchorage-independent growth and invasion to both PKCi-or Par6a-deficient cells. Interestingly, addition of an equivalent amount of catalytically active MMP-3 (stromelysin 1), the MMP species most closely related to MMP-10, did not restore anchorage-independent growth or invasion, indicating that MMP-10 plays a selective role in cellular transformation downstream of PKCi and Par6a.
PKCi regulates MMP-10 expression in NSCLC tumors in nude mice
We next assessed whether PKCi regulates MMP-10 expression in NSCLC tumors in vivo. We previously showed that expression of a dominant-negative, kinasedeficient allele of PKCi (kdPKCi) in A549 NSCLC cells inhibits tumorigenicity in nude mice (Regala et al., 2005a) . A549 NSCLC cell tumors expressing kdPKCi were significantly smaller than A549 cell tumors expressing the control expression plasmid pBabe (Figure 6a ). qPCR analysis revealed a significant reduction in MMP-10 mRNA in A549/kdPKCi tumors, whereas expression of the most well-characterized MMP species expressed in these cells, MMP-2 and MMP-9, was unaffected by kdPKCi expression (Figure 6b ). Immunohistochemical analysis of A549/kdPKCi and A549/pBabe tumors confirmed reduced expression of MMP-10 protein in kdPKCi-expressing tumors (Figure 6c) . Thus, PKCi selectively regulates MMP-10 expression in NSCLC cell tumors in vivo.
Unlike most other MMP species, MMP-10 is expressed primarily in NSCLC tumor cells not the surrounding stromal elements (Cho et al., 2004; Gill et al., 2004) , a pattern of expression similar to that of PKCi in NSCLC tumors (Regala et al., 2005b) . Immunohistochemical analysis demonstrated coexpression of high levels of PKCi and MMP-10 in primary NSCLC tumor cells (Figure 6d ). Specificity of immunohistochemical staining for PKCi and MMP-10 was confirmed using an excess of antigenic peptide.
MMP-10 expression in human NSCLC tumors predicts poor survival We next assessed whether there was a direct correlation between PKCi and MMP-10 expression in NSCLC
tumors. The open source genomic profiles of 35 primary NSCLC tumor samples were organized into tertiles based on PKCi expression as described in Supplementary Materials and methods. The median value for PKCi expression for the high tertile was 1762 (n ¼ 11, range 947-4502), whereas the median value for the middle tertile was 746 (n ¼ 12, range 545-947, P>0.0007 relative to the high group) and the median for the low tertile was 357 (n ¼ 12, range 148-527, P>0.0007 relative to the high group). The analysis revealed a statistically significant correlation between PKCi and MMP-10 expression across these groups (Figure 7a ).
MMP-10 is a member of a large family of structurally related matrix metalloproteases, many members of which have been implicated in various aspects of tumor biology (Egeblad and Werb, 2002) . Therefore, linear regression analysis was used to determine whether PKCi correlated with expression of other MMP species present in the dataset. Of the 11 MMP species present, only MMP-10 expression showed a statistically significant correlation with PKCi expression (R 2 ¼ 0.61; P ¼ 0.02) demonstrating that the correlation between PKCi and MMP-10 is highly specific (Figure 7b ).
Both MMP-10 and PKCi expression is elevated in NSCLC independent of tumor stage, suggesting that elevated expression of these genes is an early event in lung carcinogenesis (Gill et al., 2004; Regala et al., 2005b) . qPCR analysis of 12 stage I NSCLC cases obtained from the Mayo Clinic lung tumor bank demonstrated a strong positive correlation between PKCi mRNA and MMP-10 mRNA abundance (r 2 ¼ 0.778, P ¼ 0.003; n ¼ 12; Figure 7c ). Furthermore, Kaplan-Meier analysis of 60 NSCLC cases for which survival data were available demonstrated that NSCLC patients whose tumors express high MMP-10 levels (top quartile) exhibited significantly worse survival than those whose tumors express low MMP-10 (bottom quartile; Figure 7d ). Thus, MMP10 expression profiling may be of prognostic significance.
Discussion
Atypical PKCi is an oncogene that drives anchorageindependent growth through the Rho family GTPase Fields and Regala, 2007) . Our data demonstrate that PKCi and PKCz play distinct roles in lung tumorigenesis; whereas PKCi is required for NSCLC transformation, PKCz is dispensible. Our results are consistent with the fact that PKCi, but not PKCz, is overexpressed in primary NSCLC tumors and cell lines, and that PRKCI is uniquely targeted for genetic alteration in NSCLC tumors (Regala et al., 2005a, b) . A major goal of this study was to identify critical target(s) of PKCi that mediate cellular transformation of NSCLC cells. Our identification of MMP-10 as a critical effector of oncogenic PKCi is both surprising and novel. The MMPs are a large family of structurally related zinc-dependent endoproteases that play central roles in tumor invasion, metastasis, angiogenesis and tumor cell proliferation (Egeblad and Werb, 2002) . However, relatively little is known about MMP-10 function in human cancer. The stromelysin subfamily of MMPs (stromelysin 1 (MMP-3), stromelysin 2 (MMP-10) and stromelysin 3 (MMP-11)) is overexpressed in NSCLC (Delebecq et al., 2000; Bodey et al., 2001; Gill et al., 2004; Kren et al., 2006) . Interestingly, MMP-3 and MMP-11 are predominantly expressed in stromal elements surrounding lung tumors whereas MMP-10 is highly overexpressed in NSCLC tumor cells but not stroma (Gill et al., 2004) . MMP-10 expression is elevated in NSCLC tumors independent of tumor grade, stage, type or lymph node status, suggesting that MMP-10 is associated with early tumor growth (Gill et al., 2004) . Interestingly, higher levels of MMP-10 are observed in primary stage IB NSCLC tumors that recur following surgical resection (Cho et al., 2004) , suggesting that MMP-10 expression could be useful in identifying NSCLC patients at high risk of recurrence. Our data also indicate that MMP-10 expression profiling may be of prognostic significance. Interestingly, MMP-10 overexpression has also been observed in squamous cell carcinomas of the head and neck (Muller et al., 1991; O-Charoenrat et al., 2001) , oral cavity (Impola et al., 2004) and esophagus (Mathew et al., 2002) . These tumor types harbor frequent chromosome 3q26 and PRKCI amplification (Pimkhaokham et al., 2000; Imoto et al., 2001; Snaddon et al., 2001; Osada and Takahashi, 2002) . It is tempting to speculate that these tumors overexpress MMP-10 as a result of PRKCI amplification and resultant PKCi overexpression.
Despite a considerable literature demonstrating that MMP-10 is overexpressed in human tumors, only one study has assessed the potential functional role of MMP-10 in tumorigenesis. Overexpression of exogenous MMP-10 in mouse T-cell lymphoma cells leads to more rapidly growing tumors in nude mice than control cells, suggesting a role for MMP-10 in lymphoma cell growth (Van Themsche et al., 2004) . However, the question of whether endogenous MMP-10 was required for tumor growth was not assessed in this study. Our current study provides direct evidence that MMP-10 is a critical effector of the PKCi-Par6a-Rac1 signaling axis that is required for anchorage-independent growth and invasion of NSCLC cells. The fact that recombinant active MMP-10, but not MMP-3, can support NSCLC transformation suggests that these two highly related MMP species serve distinct, nonoverlapping functions in NSCLC cell biology. Future investigation will be required to elucidate the molecular mechanism(s) by which MMP-10 exerts its oncogenic effects. In summary, our present study provides important new insights into the role of PKCi signaling in NSCLC transformation. We demonstrate that Par6a plays a critical role in transformation as a component of an oncogenic PKCiPar6a-Rac1 signaling axis that drives anchorage-independent growth and invasion through specific induction of MMP-10 expression. Our data also demonstrate that MMP-10 may be a useful prognostic marker for NSCLC patients, and an attractive target for development of targeted therapies for treatment of NSCLC.
Materials and methods
Cell lines, antibodies and enzymes
Human H1703 and A549 NSCLC cell lines were obtained from American Type Culture Collection (Manassas, VA, USA) and maintained as suggested by the supplier. Antibodies used were as follows: PKCi (BD Transduction Laboratories, Franklin Lakes, NJ, USA) cat no. 610176 for immunoblot analysis; Santa Cruz Biotechnology (sc-727) for immunohistochemistry), PKCz (Cell Signaling, Beverly, MA, USA, 9372), actin (Cell Signaling 14967), FLAG (Sigma A-8592), Rac1 (BD Transduction Laboratories 610651), GFP (Molecular Probes/Invitrogen, Carlsbad, CA, USA, A11120) and MMP-10 (Abcam 38930). The MMP inhibitor GM6001 was from Calbiochem, San Diego, CA, USA (364206). Recombinant human MMP-10 (30.7 U/mg; 1 U ¼ 100 pmol/min at 37 1C) was obtained from Biomol (SE-329). Recombinant human PKCi and PKCz proteins were from Upstate Biotechnology (Lake Placid, NY, USA). Recombinant human MMP-3 (81 U/mg) was a generous gift from Dr E Radisky (Mayo Clinic, Jacksonville, FL, USA).
Lentiviral RNAi-mediated gene knockdown and qPCR Lentiviral vectors containing short hairpin RNAi against human PKCi, PKCz, Par6a, Rac1 and MMP-10 were obtained from Sigma-Aldrich Mission shRNA library (St Louis, MO, USA). A nontarget control lentiviral vector containing a short hairpin that does not recognize any human or mouse genes (NT-RNAi) was used as a negative control in all RNAi experiments. For RNAi transfection, cells were seeded in 100-mm plates and grown to 70-80% confluency. The supernatant was removed from the cells and 3 ml of complete culture media containing polybrene (6 mg/ml) was added. After 10 min at room temperature, 400 ml of viral supernatant (multiplicity of infection B3) was added. Following 24 h incubation at 37 1C, cells were washed and grown for 24 h in 10 ml of fresh culture media containing 10% fetal bovine serum. Populations of stably transfected cells were selected in 5 mg/ml puromycin. RNAi constructs were analysed for efficiency of target gene knockdown using qPCR assays using TaqMan technology from Applied Biosystems (Foster City, CA, USA). All RNAi target sequences used in this study are provided in supplemental materials (Supplementary Figure  1) . qPCR assays and reagents for human PKCi, PKCz, Par6a, Par6b, Par6g, Rac1, MMP-2, MMP-9 and MMP-10 were obtained from Applied Biosystems and gene expression was analysed on an Applied Biosystems 7900HT sequence analyser.
Soft agar growth assays
Anchorage-independent growth was assayed by the ability of cells to grow as colonies in soft agar as described previously (Regala et al., 2005a) . In some cases, the selective MMP inhibitor GM6001 (20 mM) was added to the agar. Cell colonies were visualized and quantified under a dissecting microscope (Olympus, Melville, NY, USA) after 4 weeks in culture.
Three-dimensional cultures H1703 cell transfectants were seeded into 96-well plates (1000 cells per well) onto a layer of 35 ml of Matrigel Growth Factor Reduced Basement Membrane Matrix (BD Biosciences, San Jose, CA, USA). Once attached, 150 ml of 10% Matrigel Basement Membrane Matrix containing 1% serum diluted in culture medium was placed on top of the cells. This top layer was removed and replenished every other day. Cells were visualized microscopically (Olympus) 7 days after plating and cell were photographed to observe cellular morphology. Images were captured using ImagePro software.
Cellular invasion assay
Cellular invasion was measured in 24-well plate transwell chambers containing inserts coated with Matrigel basement membrane (Corning Costar, Cambridge, MA, USA) as described previously . In some experiments, the selective MMP inhibitor GM6001 (20 mM) was added to medium in the upper and lower chambers. Cell attachment was verified using control inserts coated with collagen (Becton Dickinson, Franklin Lakes, NJ, USA) and was unaffected by any of the genetic disruptions.
Immunohistochemistry
Immunohistochemistry was performed on 5-mm paraffinembedded sections as described previously (Regala et al., 2005b) . PKCi was detected using a PKCi antibody (1:400 dilution in phosphate buffered saline (PBS)/Tween 20; Santa Cruz Biotechnology, Santa Cruz, CA, USA) and MMP-10 was detected using an MMP10 antibody (1:100 dilution in PBS/Tween 20; Abcam, Cambridge, MA, USA). Specificity of immunostaining was confirmed by antigen peptide competition in which a 200-fold molar excess of PKCi or MMP-10 peptide (provided by antibody supplier) was preincubated overnight at 4 1C with aliquots of the appropriately diluted antibody prior to use. Images were captured using the ScanScope scanner (Aperio Technologies, Vista, CA, USA) and analysed using Aperio ImageScope software.
Analysis of NSCLC tumors grown in nude mice for MMP expression A549 human NSCLC cells stably infected with recombinant retrovirus (pBabe) containing a dominant-negative, kinasedeficient human PKCi mutant allele (kdPKCi) or empty control pBabe virus (Regala et al., 2005a) were injected subcutaneously into athymic nude mice (Harlan-SpragueDawley, Indianapolis, IN, USA) and allowed to establish ectopic tumors as described previously (Regala et al., 2005a) . Tumors were excised 30 days after inoculation and RNA extracted for qPCR analysis of mRNA abundance as described previously (Regala et al., 2005a) . qPCR assay reagents for human MMP-2, MMP-9 and MMP-10 were obtained from Applied Biosystems. The use of nude mice, and all animal procedures, was authorized under an approved IACUC protocol.
Catalytic MMP enzyme assay MMP activity was measured using a colorimetric assay and the thiopeptolide substrate acetyl-Pro-Leu-Gly-S-Leu-Leu-Gly-OEt (Biomol International, Plymouth Meeting, PA, USA). Enzymatic hydrolysis of the thioester bond produces a sulfhydryl group, which reacts with DTNB [5,5 0 -dithiobis(2-nitrobenzoic acid), Ellman's reagent] to form 2-nitro-5-thiobenzoic acid, which is detected by an increase in absorbance at 412 nm (e ¼ 13 600 /M/cm at pH X6.0). Substrate hydrolysis was monitored on a Varian Cary 100 UV/Vis spectrophotometer equipped with a Peltier-thermostatted multicell changer at 37 1C, and initial rates were determined from the linear phase of reaction. MMP-3 enzyme concentration (0.97 mg/ml) was determined by UV absorbance at 280 nm, using a calculated molar extinction coefficient of 28 420/M/cm. MMP-10 enzyme concentration was 0.45 mg/ml as indicated by the manufacturer. Equal amounts of MMP-3 or MMP-10 activity (10 U/ml) was added to H1703 cell cultures and assessed for invasion and soft agar growth described above.
